KVUE

Defensive

Kenvue

Price Chart

Market Data

Financials

XBRL · SEC EDGAR

2022–2025(5yr)

Revenue

Net Income

Free CF

Metric	FY 2022	FY 2023	FY 2023	FY 2024	FY 2025Latest	YoY
Revenue	$15.1B	$14.9B	$15.4B	$15.5B	$15.1B	-2.1%
Gross Profit	$8.4B	$8.3B	$8.6B	$9.0B	$8.8B	-1.9%
Gross Margin	55.9%	55.4%	56.0%	58.0%	58.1%	+0.2pp
Operating Income	$2.9B	$2.7B	$2.5B	$1.8B	$2.4B	+31.1%
Operating Margin	19.4%	17.9%	16.3%	11.9%	16.0%	+4.0pp
Net Income	$2.1B	$2.1B	$1.7B	$1.0B	$1.5B	+42.7%
Net Margin	13.8%	13.8%	10.8%	6.7%	9.7%	+3.1pp
Free Cash Flow	$39.0M	$2.1B	$2.7B	$1.3B	$1.7B	+29.0%
FCF Margin	0.3%	14.4%	17.5%	8.6%	11.4%	+2.7pp
EPS (Diluted)	$1.21	$1.20	$0.90	$0.54	$0.76	+40.7%

Total Debt$7.7B

Cash & Equiv.$1.1B

Net Debt$6.6B

3 min read

1. THE BIG PICTURE

Kenvue is a company in a state of permanent transition, moving directly from its separation from Johnson & Johnson into a definitive merger with Kimberly-Clark. While it remains the world’s largest pure-play consumer health company, its "iconic" brand status is being tested by a combination of organic sales declines in its Self Care segment and a legal environment that threatens the reputation of its most essential ingredients (10-K Item 1, 8-K).

2. WHERE THE RISKS HIT HARDEST

Kenvue’s primary strength—a brand portfolio backed by scientific credibility—is directly threatened by regulatory and legal scrutiny over ingredients like acetaminophen and talc. Allegations regarding neurological risks associated with Tylenol ingredients strike at the heart of the "healthcare professional recommendation" model that Kenvue cites as a competitive moat (10-K Item 1, 10-Q). Furthermore, its operational flexibility is jeopardized by the Kimberly-Clark merger, as the significant indebtedness expected to be incurred by the combined company may force Kenvue to delay capital expenditures or dispose of assets to service debt (Risks).

3. WHAT THE NUMBERS SAY TOGETHER

The financial data reveals a business that is highly profitable but structurally shrinking. While Kenvue maintains an operating margin of 16.6%—ranking second among its peer group—its revenue growth is negative 2.1% on a trailing-twelve-month basis (XBRL). The most recent quarter showed a 3.2% sales increase, but management attributed this largely to a "favorable year-ago comparison" rather than a fundamental shift in demand (8-K).

The divergence between segments is stark: Essential Health grew 6.1%, while the Self Care segment—home to Tylenol and Zyrtec—saw organic sales decline by 1.2% (8-K). This suggests that Kenvue’s most science-dependent products are underperforming its everyday health categories. With short interest at 3.2% of the float, market sentiment remains cautious despite a high 4.6% dividend yield (Supplemental Signals).

4. IS IT WORTH IT AT THIS PRICE?

At a 15.0x forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, Kenvue trades at a 33% discount to the peer median of 22.3x (Peer Benchmarking). According to the CAPM analysis, the market is pricing in a long-term growth rate of just 0.4%. This low valuation appears to be a direct reflection of the "transition risks" and the "increased indebtedness" associated with the Kimberly-Clark transaction.

While Kenvue’s 16.6% operating margin is superior to peers like Kimberly-Clark (11.5%) and Kraft Heinz (-23.4%), its FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margin of 7.7% is near the bottom of the group (Peer Benchmarking). For the current price to be justified, Kenvue must prove it can stabilize its Self Care organic growth; if growth remains stagnant or legal expenses from the acetaminophen and talc litigation spike, the 15.0x multiple may still be vulnerable (CAPM analysis).

5. WHAT WOULD CHANGE THIS VIEW?

Constructive if the FDA denies the citizen petition regarding acetaminophen, which would significantly lower the legal risk profile for the Tylenol brand (10-Q).
Cautious if the Kimberly-Clark merger closing is delayed beyond the second half of 2026, or if the combined company’s leverage prevents the execution of the "Our Vue Forward" restructuring program (10-K Item 1, 8-K).
Cautious if FCFFCFFree Cash Flow — cash left after paying for operations and capital investments; what the company can actually spend, save, or return to shareholders margins continue to lag peers, suggesting that Kenvue's high operating profits are not successfully converting into cash available for shareholders.

6. BOTTOM LINE

Structural Advantage: A science-backed brand portfolio with high operating margins and a hybrid manufacturing model that provides significant scale.

Bottom Line: Kenvue is a high-yield value play whose upside is currently capped by merger-related debt and a cloud of unresolved product litigation.

Source: Synthesis · LLM Analysis

3 min read

1. Top 5 Material Risks

Proposed Transaction Integration: The merger with K-C may fail to realize projected synergies or cost savings, potentially leading to the loss of key personnel, operational disruption, and unforeseen expenses that could adversely affect the combined company’s financial condition.
Increased Indebtedness: K-C is expected to incur significant additional debt to finance the transaction, which will reduce the cash flow available for debt service and may force the combined company to delay capital expenditures or dispose of material assets.
Competitive Pressures: Kenvue operates in highly competitive markets where private-label and generic products often undercut prices, potentially forcing Kenvue to lower prices to maintain market share, thereby reducing gross margins.
Product Ingredient Concerns: Litigation and regulatory actions concerning the safety of ingredients such as acetaminophen, talc, and phenylephrine have resulted in, and could continue to cause, product recalls, reformulations, and significant legal expenses.
Reliance on Third Parties: Kenvue depends on third-party manufacturers and suppliers for key products like Tylenol® and Zyrtec®; disruptions at these facilities or failures to meet quality standards could lead to product shortages and lost sales.

2. Company-Specific Risks

Separation from J&J: Kenvue may not achieve the expected benefits of its separation from Johnson & Johnson, and Kenvue remains subject to potential tax-related liabilities and indemnification obligations to J&J.
Digital Strategy Execution: The transition to a digital-first model, including e-commerce and connected health apps, exposes Kenvue to new risks regarding data privacy, cybersecurity, and the rapid pace of technological change.
Artificial Intelligence Governance: The pilot use of generative AI in supply chain and content creation creates risks of unintended consequences, flawed outputs, and potential intellectual property infringement that could damage the brand.
Talc-Related Liabilities: While J&J has agreed to indemnify Kenvue for certain talc-related liabilities in the U.S. and Canada, Kenvue remains solely responsible for talc-related claims arising outside of those regions.

3. Regulatory/Legal Risks

FDA and Regulatory Orders: The FDA has issued a proposed order to remove oral phenylephrine from the OTC monograph, which has already led to class-action lawsuits and could result in the removal of products from the market.
Environmental Compliance: Kenvue is involved in proceedings under the Comprehensive Environmental Response, Compensation, and Liability Act (Superfund) and faces potential remediation costs for historical contamination at current or former properties.
Data Privacy Laws: Kenvue is subject to complex global privacy frameworks, including the GDPR, the California Consumer Privacy Act, and China’s PIPL, where non-compliance could result in substantial fines and reputational damage.
Tax Audits: Kenvue is subject to regular tax examinations globally; adverse positions taken by tax authorities could result in material liabilities, including interest and penalties, in excess of current reserves.

4. Financial Impact Map

Proposed Transaction Integration → Operating Expenses → Significant non-recurring costs including legal, financial advisory, and severance/employee benefit-related expenses. Increased Indebtedness → Cash Flow from Operations → Reduced cash flow available to service debt obligations, potentially limiting capital expenditures. Competitive Pressures → Net Sales / Gross Margin → Potential price reductions to maintain volume against private-label and generic competitors. Product Ingredient Concerns → Legal Accruals / Net Income → Significant expenses from settlements, judgments, or product recalls potentially in excess of accruals. Reliance on Third Parties → Cost of Goods Sold / Net Sales → Increased costs to source alternative manufacturers or lost sales due to supply chain disruptions.

Source: 10-K Item 1A · LLM Analysis

Recent Filings

Form	Filed	Period
10-K	Feb 2026	Dec 2025
8-K	Feb 2026	—
10-Q	Nov 2025	Sep 2025
14A	Apr 2025	—